Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Palmitoyl pentapeptide-4 is a synthetic fatty acid-linked peptide (Pal-Lys-Thr-Thr-Lys-Ser) used primarily in anti-aging skincare products. It is a "matrikine" that mimics a fragment of Type I collagen, acting as a cellular messenger to stimulate the synthesis of extracellular matrix (ECM) components. Developed by Sederma (now part of Croda International) and widely commercialized by Procter & Gamble in the Olay Regenerist line, it promotes the production of collagen types I, III, and IV, elastin, and glycosaminoglycans by fibroblasts in the dermis. Recent research presented at the AAD Annual Meeting 2026 indicates that it also upregulates genes involved in cell adhesion and tight junction formation in keratinocytes, thereby enhancing skin barrier integrity and mechanical stability. It is frequently used in combination with other peptides to improve overall skin health and reduce the appearance of fine lines and wrinkles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on palmitoyl pentapeptide-4.